分子之心获逾亿美元A轮融资，加速打造AI蛋白质设计基础设施
英文摘要
MoleculeMind, an AI protein design platform, has completed a Series A funding round totaling over $100M from investors including Bluebridge Capital, Pudong Venture Capital, COFCO Emerging Industry Fund, and others, with existing investors like Cathay Biotech also participating. The company unveiled MMDesign, an AI-driven de novo antibody design platform that achieved over 90% target hit rate on 12 real clinical targets and delivered picomolar-level affinity against the challenging TNFα target after testing only 14–50 AI-designed candidates. Its proprietary MMFold structure prediction engine outperforms Google AlphaFold 3 and all open-source models on the FoldBench antibody-antigen interface benchmark. MoleculeMind has built MoleculeOS, an AI-native protein engineering infrastructure based on its NewOrigin multimodal foundational model, which has been validated in industrial collaborations across drug discovery, green biomanufacturing, and novel materials. The company has established multi-layer commercial partnerships with top global pharma, synthetic biology firms, and chemical groups, demonstrating strong product-market fit and creating a closed-loop data flywheel from wet-lab-verified projects.
中文摘要
AI蛋白质设计平台分子之心完成逾亿美元A轮融资，投资方包括蓝桥资本、浦东创投、中粮新兴产业基金等，老股东凯赛生物等继续追加。公司发布AI从头设计平台MMDesign，在12个真实临床靶点中实现超90%命中率，针对TNFα等超难靶点仅需验证14-50个AI设计分子即可获得皮摩尔级亲和力抗体。自研高精度结构预测底座MMFold在FoldBench抗体-抗原界面测试中全面超越AlphaFold 3及所有开源模型。分子之心构建了以NewOrigin多模态大模型为基础的AI原生生物工程基础设施MoleculeOS，已与全球顶尖药企、合成生物学龙头、化工新材料集团等实现商业化合作，通过湿实验验证的工业项目驱动数据飞轮，确立全球AI蛋白质领域产业化领先地位。
关键要点
MoleculeMind closed over $100M Series A financing from a consortium of strategic, industrial, and financial investors, signaling strong capital conviction in AI-driven protein design infrastructure.
分子之心完成逾亿美元A轮融资，由蓝桥资本、浦东创投、中粮基金等产业与财务资本共同注资，显示资本对AI蛋白质基础设施的强烈信心。
The MMDesign platform demonstrated >90% target hit rate on 12 clinical targets, requiring only 14–50 AI-designed molecules to achieve picomolar-level affinities even for difficult targets like TNFα.
MMDesign平台在12个临床靶点中实现超90%命中率，针对TNFα等超难靶点仅需验证14-50个分子即可获得皮摩尔级亲和力抗体。
MMFold structure prediction engine surpassed AlphaFold 3 and all open-source models on antibody-antigen interface benchmarks, marking a shift from catching up to leading in industrial-grade AI protein design.
自研MMFold在抗体-抗原界面预测精度上超越AlphaFold 3及所有开源模型，标志着中国团队在AI蛋白质工业核心赛道实现从追赶到领跑。
MoleculeOS, an AI-native protein engineering infrastructure built on the NewOrigin multimodal model, has been validated in multiple industrial partnerships and creates a closed-loop data flywheel from wet-lab results.
基于NewOrigin多模态大模型构建的AI原生蛋白质工程基础设施MoleculeOS已获多家产业头部客户验证，形成‘AI设计-湿实验验证-模型进化’的数据飞轮护城河。
Commercial traction includes platform licensing to top pharma, joint R&D for hard targets, and self-developed early assets, with customers initiating repeat projects across multiple modalities.
商业模式覆盖平台授权、联合研发与自研管线，合作伙伴涵盖跨国药企、合成生物学龙头等，多客户连续多项目合作，体现强粘性与跨领域价值。